Quest Diagnostics price target raised to $165 from $160 at Mizuho

Mizuho analyst Ann Hynes raised the firm’s price target on Quest Diagnostics to $165 from $160 and keeps a Buy rating on the shares. The analyst believes managed care and drug distributors’ earnings visibility remains good, but she incrementally believes hospitals have the most improved outlook. Earnings visibility for the acute care sector is high for 2023, given the likely continued recovery in baseline utilization and the stabilization/improvement in labor, Hynes tells investors in a research note.